Reviewing ProQR Therapeutics (PRQR) & The Competition

ProQR Therapeutics (NASDAQ:PRQR) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare ProQR Therapeutics to related businesses based on the strength of its profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Earnings and Valuation

This table compares ProQR Therapeutics and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
ProQR Therapeutics	$17.99 million	-$47.73 million	-3.07
ProQR Therapeutics Competitors	$727.61 million	$12.25 million	-10.38

ProQR Therapeutics’ peers have higher revenue and earnings than ProQR Therapeutics. ProQR Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and price targets for ProQR Therapeutics and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1	1	6	0	2.62
ProQR Therapeutics Competitors	9792	15071	45345	1573	2.54

ProQR Therapeutics currently has a consensus price target of $7.60, suggesting a potential upside of 439.01%. As a group, “Biotechnology” companies have a potential upside of 93.65%. Given ProQR Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe ProQR Therapeutics is more favorable than its peers.

Volatility and Risk

ProQR Therapeutics has a beta of 0.29, meaning that its stock price is 71% less volatile than the S&P 500. Comparatively, ProQR Therapeutics’ peers have a beta of 1.15, meaning that their average stock price is 15% more volatile than the S&P 500.

Profitability

This table compares ProQR Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-223.51%	-73.83%	-35.14%
ProQR Therapeutics Competitors	-9,051.23%	-201.20%	-30.64%

Summary

ProQR Therapeutics peers beat ProQR Therapeutics on 7 of the 12 factors compared.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.